Yon sijè nan diskisyon yo pral vaksen Konbinezon Novavax 'COVID-NanoFlu™, ki konbine kandida pou vaksen COVID-19 ak NanoFlu™ ki baze nan pwoteyin nanopatikil rekonbinan konpayi an ak adjuvant Matrix-M™ nan yon sèl fòmilasyon.
Detay sesyon yo jan sa a:
| Dat: Mèkredi 20 oktòb 2021 |
| Lè: 11:30 am – 12:00 pm Tan Ewopeyen Santral (CET) / |
| 5:30 am – 6:00 am Lè solèy leve (EDT) |
| Tit: Mizajou sou vaksen Novavax nan NanoFlu ak devlopman vaksen konbinezon COVID-19-NanoFlu |
| Patisipan Novavax: Vivek Shinde, MD, Vis Prezidan, Devlopman klinik |
Pwopriyetè platfòm teknoloji recombinant konpayi an konbine pouvwa ak vitès jeni jenetik pou pwodwi avèk efikasite nanopartikul trè iminitè ki fèt pou adrese bezwen sante mondyal ijan. Novavax ap fè esè klinik an reta pou NVX-CoV2373, kandida vaksen li kont SARS-CoV-2, viris ki lakòz COVID-19 la. NanoFlu™, vaksen nan nanopartikul grip kwadrivalan li a, te atenn tout objektif prensipal yo nan esè klinik pivotal Faz 3 li sou granmoun aje yo. Tou de kandida vaksen yo enkòpore adjuvant Matrix-M™ ki baze sou saponin pwopriyetè Novavax pou amelyore repons iminitè a epi ankouraje nivo segondè nan antikò netralize.
KISA POU RETIRE NAN ATIK SA A:
- NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.
- The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs.
- Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
